

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute of Child Health and Human Development; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Child Health and Human Development Special Emphasis Panel (SEP) meeting:

Name of SEP: Specialized Clinical Fellowship and Mentored Specialized Clinical Investigator Award (Teleconference).

Date: May 12, 1998.

Time: 4:30 p.m.—adjournment.

Place: 6100 Executive Boulevard, 6100 Building, Room 5E01, Rockville, Maryland 20852.

Contact Person: Gopal Bhatnagar, Ph.D., Scientific Review Administrator, NICHD, 6100 Executive Boulevard, Room 5E01, Rockville, MD 20852, Telephone: 301-496-1485.

Purpose/Agenda: To evaluate and review research grant applications.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The discussion of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with these applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. [93.864, Population Research and No. 93.865, Research for Mothers and Children], National Institute of Health, HHS)

Dated: April 28, 1998.

LaVerne Y. Stringfield,

Committee Management Office, NIH.

[FR Doc. 98-11925 Filed 5-4-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel meeting:

Name of Sep: ZDK1 GRB-6 (01 P).

Date: June 8-10, 1998.

Time: 6:00 PM.

Place: Omni New Haven Hotel, 155 Temple Street, New Haven, Connecticut 06510, Telephone: (203) 772-6664.

Contact: Neal Musto, Ph.D., Scientific Review Administrator, Review Branch, DEA, NIDDK, Natcher Building, Room 6AS-37A, National Institutes of Health, Bethesda, Maryland 20892-6600, Phone: (301) 594-7798.

Purpose/Agenda: To review and evaluate grant applications.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.847-849, Diabetes, Endocrine and Metabolic Diseases; Digestive Diseases and Nutrition; and Kidney Diseases, Urology and Hematology Research, National Institutes of Health.)

Dated: April 29, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-11927 Filed 5-4-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute on Aging; Amended Notice of Meeting of the National Advisory Council on Aging**

Notice is hereby given of a change in the agenda for the meeting of the National Advisory Council on Aging, National Institute on Aging, May 21-22, 1998, to be held at the National Institutes of Health, Building 31, Conference Room 6, Bethesda, Maryland published in the **Federal Register** on April 21, 1998, (63 FR 19737). This meeting was scheduled to be open to the public on Thursday, May 21, from 1:30 to 4:15 p.m. and Friday, May 22, from 8:00 a.m. until adjournment. The meeting was scheduled to be closed on Thursday, May 21 from 4:15 p.m. to recess.

The meeting will now be closed to the public on Thursday, May 21, from 2:30 p.m. until recess. The meeting will be open on Friday, May 22 from 8:00 a.m. to adjournment.

Dated: April 29, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-11928 Filed 5-4-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel meeting.

Name of SEP: ZDK1 GRB-8 03 P.

Date: May 27-29, 1998.

Time: 6:00 PM.

Place: Union Station Hotel, 1001 Broadway, Nashville, Tennessee 37203, Telephone: (615) 726-1001.

Contact: Roberta Haber, Ph.D., Scientific Review Administrator, Review Branch, DEA, NIDDK, Natcher Building, Room 6AS-25N, National Institutes of Health, Bethesda, Maryland 20892-6600, Phone: (301) 594-8898.

Purpose/Agenda: To review and evaluate grant applications.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.847-849, Diabetes, Endocrine and Metabolic Diseases; Digestive Diseases and Nutrition; and Kidney Diseases, Urology and Hematology Research, National Institutes of Health.)

Dated: April 29, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-11929 Filed 5-4-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institutes of Allergy and Infectious Diseases; Notice of Meeting: Allergy, Immunology, and Transplantation Research Committee**

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Allergy, Immunology, and Transplantation Research Committee on June 3-5, 1998, at the Historic Inns of Annapolis Maryland Inn, 58 State Circle, Annapolis, Maryland.

The meeting will be open to the public from 8:30 a.m. to 9:30 a.m. on

June 3 to discuss administrative details relating to committee business and program review, and for a report from the Director, Division of Extramural Activities, which will include a discussion of budgetary matters. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sections 10(d) of Public Law 92-463, the meeting will be closed to the public for the review, discussion, and evaluation of individual grant applications and contract proposals from 9:30 a.m. on June 3 until adjournment on June 5. These applications, proposals, and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. Claudia Goad, Committee Management Officer, National Institute of Allergy and Infectious Diseases, Solar Building, Room 3C26, National Institutes of Health, Bethesda, Maryland 20892, 301-496-7601, will provide a summary of the meeting and a roster of committee members upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Goad in advance of the meeting.

Dr. Kevin M. Callahan, Scientific Review Administrator, Allergy, Immunology, and Transplantation Research Committee, NIAID, NIH, Solar Building, Room 4C20, Bethesda, Maryland, telephone 301-496-8424, will provide substantive program information.

(Catalog of Federal Domestic Assistance Program Nos. 93-855, Immunology, Allergic and Immunologic Diseases Research, National Institutes of Health.)

Dated: April 28, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-11930 Filed 5-4-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Highly Informative Microsatellite Repeat Polymorphic DNA Markers

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is a notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license in the United States to practice the inventions embodied in U.S. Patent Application Serial No. 07/799,828 (issued as Patent No. 5,378,602 on January 3, 1995), entitled "Twenty-Seven Highly Informative Microsatellite Repeat Polymorphic DNA Markers"; U.S. Patent Application Serial No. 07/922,723 (issued as Patent No. 5,369,004 on November 29, 1994), entitled "Five Highly Informative Microsatellite Repeat Polymorphic DNA Markers"; U.S. Patent Application Serial No. 07/952,277, entitled "Eleven Highly Informative Microsatellite Repeat Polymorphic DNA Markers"; U.S. Patent Application Serial No. 08/074,275 (issued as Patent No. 5,468,610 on November 21, 1995), entitled "Three Highly Informative Microsatellite Repeat Polymorphic DNA Markers"; and U.S. Patent Application Serial No. 08/480,366 (issued as Patent No. 5,721,100 on February 24, 1998), entitled, "Three Highly Informative Microsatellite Repeat Polymorphic DNA Markers" to Lifecodes Corporation, having a place of business in Stamford, Connecticut. The patent rights in these inventions have been assigned to the United States of America.

The field of use would be DNA profiling assays for detecting polymorphisms of forensic and medical samples including blood, semen, tissue hair, saliva, urine, and mixtures of body fluids.

DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 6, 1998, will be considered.

ADDRESSES: Requests for a copy of the patents, patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Charles Maynard, M.P.H., Technology Licensing Specialist, Office of Technology Transfer, National

Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD 20852-3804; Telephone: (301) 496-7735, ext. 243; Facsimile: (301) 402-0220. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

SUPPLEMENTARY INFORMATION: A novel group of microsatellite repeat polymorphic deoxyribonucleic acid (DNA) markers is valuable for rapidly identifying and differentiating between individual human DNA sequences for forensic, genetic, and human DNA mapping studies. These nucleotides can also be used for paternity and prenatal screening, and genetic mapping. These new microsatellite DNA markers can be used as primers for rapid polymerase chain reaction (PCR) amplification of unique human DNA polymorphisms, which are naturally occurring mutations in DNA sequences that are often unique on the basis of as little as a single nucleotide sequence. Assays using these nucleotides are based on PCR and therefore need only small amounts of test DNA. The assays are easy to perform and relatively inexpensive and results can be obtained in less than 24 hours, compared with 3 or 4 days for other similar tests. Accordingly, the invention also relates to an improved PCR procedure and a PCR assay kit which comprise nucleotides according to the invention. The invention describes a method of the steps involved in extracting DNA from a sample to be tested, amplifying the extracted DNA and identifying the amplified extension products for each different sequence. Each different sequence is differentially labeled. The method is applicable to a wide variety of forensic and medical samples as stated above.

DNA identity testing has revolutionized the field of forensic analysis of biological materials. The forensic test compares the genetic material in biologic specimens from a crime scene to that taken from a suspect. DNA testing transforms the DNA found in blood, serum, or other tissue from a crime scene or an individual into a unique genetic profile. The profile may serve as a means of making a positive identification in a rape, murder, or other violent crime. A number of loci in this application may also be useful in identity testing by discerning a DNA pattern that is unique to an individual.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C.